Erin JD - Shattuck Labs Corp Counsel
| STTK Stock | USD 1.09 0.01 0.93% |
Insider
Erin JD is Corp Counsel of Shattuck Labs
| Age | 44 |
| Address | 500 West 5th Street, Austin, TX, United States, 78701 |
| Phone | 512 900 4690 |
| Web | https://www.shattucklabs.com |
Shattuck Labs Management Efficiency
The company has return on total asset (ROA) of (0.3974) % which means that it has lost $0.3974 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6848) %, meaning that it created substantial loss on money invested by shareholders. Shattuck Labs' management efficiency ratios could be used to measure how well Shattuck Labs manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.57. The value of Return On Capital Employed is expected to slide to -0.65. At this time, Shattuck Labs' Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 206.4 M this year, although the value of Non Current Liabilities Total will most likely fall to about 3.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Mack | Pmv Pharmaceuticals | 62 | |
| Gwenn Hansen | Nurix Therapeutics | 53 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Stewart Fisher | C4 Therapeutics | 57 | |
| Jared MD | Kymera Therapeutics | 59 | |
| Steven Bellon | Foghorn Therapeutics | 59 | |
| Michael Rap | Nurix Therapeutics | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Vijay Sabesan | Kymera Therapeutics | 52 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Carlos Costa | Foghorn Therapeutics | 51 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Ben Strain | Foghorn Therapeutics | N/A | |
| Kelly Schick | C4 Therapeutics | 44 | |
| James JD | Eliem Therapeutics | 58 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| JD Esq | Nurix Therapeutics | 63 | |
Management Performance
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.4 |
Shattuck Labs Leadership Team
Elected by the shareholders, the Shattuck Labs' board of directors comprises two types of representatives: Shattuck Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shattuck. The board's role is to monitor Shattuck Labs' management team and ensure that shareholders' interests are well served. Shattuck Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shattuck Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Conor CPA, Vice Relations | ||
| Thomas PharmD, Senior Affairs | ||
| Andrew MBA, Chief Officer | ||
| Fatima MD, VP Research | ||
| George Fromm, CoChief Officer | ||
| Stephen JD, Corporate Counsel | ||
| Kelli MS, Senior Quality | ||
| Abhinav Shukla, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Suresh Silva, CoChief Officer | ||
| Conor Richardson, Sr Relations | ||
| Erin JD, Corp Counsel | ||
| Casi DeYoung, Chief Officer |
Shattuck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Shattuck Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (14.27) % | ||||
| Current Valuation | (34.88 M) | ||||
| Shares Outstanding | 47.74 M | ||||
| Shares Owned By Insiders | 13.41 % | ||||
| Shares Owned By Institutions | 74.67 % | ||||
| Number Of Shares Shorted | 2.12 M | ||||
| Price To Book | 0.53 X | ||||
| Price To Sales | 12.62 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Shattuck Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Shattuck Stock please use our How to buy in Shattuck Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shattuck Labs. If investors know Shattuck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shattuck Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 0.088 | Quarterly Revenue Growth 7.045 | Return On Assets (0.40) | Return On Equity (0.68) |
The market value of Shattuck Labs is measured differently than its book value, which is the value of Shattuck that is recorded on the company's balance sheet. Investors also form their own opinion of Shattuck Labs' value that differs from its market value or its book value, called intrinsic value, which is Shattuck Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shattuck Labs' market value can be influenced by many factors that don't directly affect Shattuck Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shattuck Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shattuck Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shattuck Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.